ライフサイエンスコーパス: AKR1B10

1 man AKR1B subfamily members (i.e. AKR1B1 and AKR1B10).

2 rated that aldo-keto reductase family 1 B10 (AKR1B10), a novel protein overexpressed in human hepatoc

3 These data suggest that AKR1B10 affects cell survival through modulating lipid s

4 acid protein with 91% amino acid identity to AKR1B10; AKR1B15.2 has a prolonged N terminus and consis

5 ntracellular fluorescent studies showed that AKR1B10 and ACCA proteins co-localize in the cytoplasm o

6 This association between AKR1B10 and ACCA proteins was further confirmed by co-im

7 cantly increased the secretion of endogenous AKR1B10 and exogenous GFP-AKR1B10 fusion protein when co

8 We characterized the functional domain in AKR1B10 and found that helix 10 (amino acids 233-240), l

9 including 3 new markers of IM (ACE2, LGALS4, AKR1B10) and 3 of SPEM (OLFM4, LYZ, DPCR1).

10 Co-immunoprecipitation with AKR1B10 antibody and protein mass spectrometry analysis

11 ed epithelium in keloid disease and identify AKR1B10 as a potential new target in future management o

12 tification of the aldo-keto reductase enzyme AKR1B10 as highly up-regulated in keloid epidermis sugge

13 n mass spectrometry analysis identified that AKR1B10 associates with acetyl-CoA carboxylase-alpha (AC

14 The cytosolic AKR1B10 associates with and is translocated to lysosomes

15 determined the transcriptional start site of AKR1B10 at 320 bp upstream of the ATG translational star

16 The results demonstrated that AKR1B10 consists of 10 exons and 9 introns, stretching a

17 on exchange chromatography demonstrated that AKR1B10 exists in two distinct forms, monomers (approxim

18 is known about the regulatory mechanisms of AKR1B10 expression.

19 tion of endogenous AKR1B10 and exogenous GFP-AKR1B10 fusion protein when cotransfected.

20 n this study, we determined the structure of AKR1B10 gene and characterized its promoter.

21 -4091 bp of the 5'-flanking fragment of the AKR1B10 gene was capable of driving GFP and luciferase r

22 namycin, a HSP90alpha inhibitor, dissociated AKR1B10-HSP90alpha complexes and significantly reduced A

23 ding is significant in exploiting the use of AKR1B10 in cancer clinics.

24 This study presents a novel function of AKR1B10 in tumorigenic mammary epithelial cells (RAO-3),

25 AKR1B10 inhibition results in apoptosis of tumor cells w

26 s exposing the HCT-8 cells to epalrestat, an AKR1B10 inhibitor, led to more than 2-fold elevation of

27 These data suggest that AKR1B10 is a novel regulator of the biosynthesis of fatt

28 In this study, we demonstrate that AKR1B10 is critical to cell survival.

29 AKR1B10 is involved in hepatocarcinogenesis via modulati

30 Our previous studies have shown that AKR1B10 is secreted through a lysosome-mediated nonclass

31 Aldo-keto reductase family 1 member B10 (AKR1B10) is overexpressed in human hepatocellular carcin

32 Aldo-keto reductase family 1 member B10 (AKR1B10) is primarily expressed in the normal human colo

33 nterestingly, small interfering RNA-mediated AKR1B10 knock down increased ACCA degradation through ub

34 Our previous studies have shown that AKR1B10 mediates the ubiquitin-dependent degradation of

35 Consistent with previous findings, AKR1B10 mRNA and protein levels were higher in primary h

36 After analyzing the correlation between AKR1B10 mRNA expression in PHC tissues and the clinical

37 A higher AKR1B10 mRNA expression level is related to a shorter DF

38 tissues and the clinical data, we found that AKR1B10 mRNA expression was associated with serum alpha-

39 through identified potential targets namely, AKR1B10, NR3C1, PTGS2, and HER2.

40 Paracrine signals released by AKR1B10-overexpressing keratinocytes into conditioned me

41 Our recent studies have showed that AKR1B10 plays a critical role in the growth and prolifer

42 umor suppressor protein binding sites in the AKR1B10 promoter, including c-Ets-1, C/EBP, AP-1, and p5

43 ntibody and pulldown assays with recombinant AKR1B10 protein.

44 Aldo-keto reductase 1B10 (AKR1B10) protein is a new tumor biomarker in humans.

45 (MUC13, OLFM4, CDH17, KRT20, MUC5AC, LGALS4, AKR1B10, REG4).

46 lipids like sphingosine-1-phosphate (S1P) in AKR1B10's oncogenic function.

47 increases QSG-7701's proliferation, in which AKR1B10-S1P signaling plays a pivotal role.

48 P90alpha complexes and significantly reduced AKR1B10 secretion in a dose-dependent manner.

49 r, our data suggest that HSP90alpha mediates AKR1B10 secretion through binding to its helix 10 domain

50 3-240), located at the C terminus, regulates AKR1B10 secretion.

51 tudy illuminates the regulatory mechanism of AKR1B10 secretion.

52 AKR1B10 silencing also increased the levels of alpha,bet

53 ls (NCI-H460), small-interfering RNA-induced AKR1B10 silencing resulted in caspase-3-mediated apoptos

54 , partially rescued the apoptosis induced by AKR1B10 silencing, whereas exposing the HCT-8 cells to e

55 Here, we show that AKR1B10 transfection into normal human keratinocytes rep

56 Cotransfection of AKR1B10 with a luciferase reporter plasmid showed reduce

57 s-240 in helix 10 mediate the interaction of AKR1B10 with HSP90alpha.